FibroBiologics, Inc.
For the period ended Dec 31, 2024. Filed Apr 23, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Dec 31, 2024 · Filed Apr 23, 2025
Contents
Appendix A – Capital INCREASE Amendment
Capital INCREASE Amendment
The Certificate of Amendment that becomes effective will not mark changes to the Amended and Restated Certificate of Incorporation as currently in effect, but this Appendix A has marked all such changes for ease of stockholder review. Words with adouble-underlineare additions to and words with astrikethrough are deletions from the Amended and Restated Certificate of Incorporation as currently in effect.
CERTIFICATE OF AMENDMENT TO
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF FIBROBIOLOGICS, INC.
FibroBiologics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows:
| 1. | The name of the Corporation is FibroBiologics, Inc. |
| 2. | Pursuant to Section 242 of the DGCL, the amendment herein set forth has been duly approved by the Board of Directors and holders of a majority of the outstanding shares of the Corporation. |
| 3. | The first sentence of Article FOURTH of the Amended and Restated Certificate of Incorporation is hereby replaced with the following: |
“The total number of shares of all classes of capital stock that the Corporation is authorized to issue is 110,000,000310,000,000 shares, consisting of (i)100,000,000300,000,000 shares of common stock, par value $0.00001 per share (“Common Stock”), and (ii) 10,000,000 shares of preferred stock, par value $0.00001 per share (“Preferred Stock”), of which 2,500 shares are designated as Series C Preferred Stock (“Series C Preferred Stock”).”
| 4. | This Certificate of Amendment was duly adopted and approved by the stockholders of this Corporation on the [XX]th day of [XX], 2025 in accordance with Section 242 of the DGCL. |
A-1
IN WITNESS WHEREOF, this Certificate of Amendment has been executed by a duly authorized officer of this Corporation on this day of , 2025.
| FIBROBIOLOGICS, INC. | |
| By: | |
| Name: | Robert Hoffman |
| Title: | Interim Chief Financial Officer |
A-2
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.